Abstract
If possible, warfarin therapy should be avoided during pregnancy. If warfarin therapy is essential, it should be avoided at least during the first trimester (because of teratogenicity) and from about two to four weeks before delivery to reduce risk of hemorrhagic complications. Unfractionated heparin or low molecular weight heparin could be substituted when appropriate because these agents do not cross the placenta and are considered the anticoagulant drugs of choice during pregnancy.
| Original language | English |
|---|---|
| Pages (from-to) | 36-37 |
| Number of pages | 2 |
| Journal | Canadian Pharmaceutical Journal |
| Volume | 135 |
| Issue number | 10 |
| State | Published - 2002 |